Day: May 1, 2024

Dayforce® recurring revenue of $337.2 million, up 24.3%, and excluding float revenue, up 23.0% Total revenue of $431.5 million, up 16.4% Operating profit of $40.7 million and adjusted operating profit of $109.1 million MINNEAPOLIS and TORONTO, May 01, 2024 (GLOBE NEWSWIRE) — Dayforce, Inc. (“Dayforce” or the “Company”) (NYSE:DAY) (TSX:DAY), a global leader in human capital management (“HCM”) technology, today announced its financial results for the first quarter ended March 31, 2024. “I am pleased to report another strong quarter for Dayforce. We grew both revenue and operating profit, and we exceeded guidance across all key revenue and profitability metrics,” said David Ossip, Chair and CEO of Dayforce. “We remain confident in the business with momentum across sales, product, and operations,...

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, May 01, 2024 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX: MHC.U; MHC.UN) today published its fourth Environmental, Social and Governance (“ESG”) Report (the “Report”). The Report showcases the REIT’s ongoing commitments to resident well-being, ethical corporate governance, energy efficiency, community service, and more. “We are excited to share our fourth annual ESG Report, which demonstrates our commitment to sustainability for our residents, our communities, and our environment,” said Kurt Keeney, Chief Executive Officer. “We continue to take purposeful steps to drive environmental and community-based value that builds on our already sustainable mission statement: to provide everyday...

WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 – 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “The 11 oral presentations at ARVO speak to the continued excitement surrounding SYFOVRE, which is the most chosen GA treatment by retina specialists,” said Caroline Baumal, M.D., chief medical officer, Apellis. “We are excited to share data that continue to highlight SYFOVRE’s ability to slow disease progression with increasing effects over time...

DAVENPORT, Iowa, May 01, 2024 (GLOBE NEWSWIRE) — Les Ottolenghi, a Fortune 500 senior technology and cybersecurity executive, has joined Lee Enterprises, Incorporated (NASDAQ:LEE), as Chief Transformation and Commercial Officer. Kevin Mowbray, Lee’s President and Chief Executive Officer, said the senior-level role was created to advance and accelerate Lee’s industry-leading digital growth and further strengthen market supremacy. “Les brings over 25 years of leadership experience in large public corporations and high-growth technology startups, with keen expertise in digital transformation, artificial intelligence developments, e-commerce, modernizing digital infrastructure, data monetization, and cybersecurity,” Mowbray said. “His addition will help Lee exceed the five-year targets in our Three-Pillar Growth Strategy of expanding...

DEA’s Reclassification of Marijuana Boosts Business Opportunities and Consumer Access, Signaling a New Era for the Cannabis Industry BOCA RATON, Fla., May 01, 2024 (GLOBE NEWSWIRE) — Springbig, a leading provider of marketing solutions for the cannabis industry, expressed their strong support for the Drug Enforcement Administration’s (DEA) decision to reclassify marijuana as a lower-risk drug, announced yesterday. Reflecting the broad societal trends in the last decade-plus, this move from the DEA proves that the federal government is finally recognizing cannabis for its true value as an industry that is positively impacting businesses and consumers alike. Jeff Harris, CEO of Springbig, commented, “The DEA’s reclassification of marijuana is a transformative development for the cannabis industry. It not only...

Strong first half 2024 execution has Company on pace for full-year targets U.S. Consumer second quarter net sales of $1.38B equal record high Q2 2024 GAAP gross margin of 30.4% and non-GAAP adjusted gross margin of 35.3% reflect 350 and 60 basis point improvements, respectively Strong free cash flow delivers net leverage of 6.95x, well below covenant maximum Q2 2024 GAAP EPS of $2.74; non-GAAP Adjusted EPS of $3.69 are ahead of plan Teams driving consumer engagement in Q3 representing 60 percent of seasonal POSMARYSVILLE, Ohio, May 01, 2024 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the world’s largest marketer of branded consumer lawn and garden as well as a leader in indoor and hydroponic growing products, today announced its results for the second quarter ended March 30, 2024. “Through the first six months...

SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. Study clinical cardiology leadership and members of the Executive Steering Committee, Dr. Carl Pepine, Professor of Medicine at the University Florida at Gainesville, and Dr. Amish Raval, Professor of Medicine at the University of Wisconsin at Madison, presented the early positive results on Tuesday, April 30, 2024 in a webcast sponsored by BioCardia. Results from the open label roll-in cohort of patients having chronic myocardial ischemia with refractory angina showed an average increase in...